RxDoctor Payments Data

Suresh Kumar Patel, MD

Cardiovascular Disease · Jonesboro, ARNPI 1588669006

Payments from drug & device makers

$941in general payments, 2019–2025

Across 21 payments — averaging $44.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$197
  • Ascensia Diabetes Care US Inc.$166
  • Amgen$121
  • Medtronic$113
  • Abiomed$77
  • Daiichi Sankyo Inc.$41
  • plus $227 from 9 others

What the payments were for

  • Food & beverage$941100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$941 in reported general payments places this provider in the 20th percentile of 130 cardiovascular disease providers in Arkansas.

See all cardiovascular disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$88,269
Medicare patients
838
Services billed
2,413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$62,329
Atorvastatin Calcium109$1,417
Metoprolol Succinate63$709
Lisinopril54$628
ClopidogrelClopidogrel Bisulfate31$504
Amiodarone Hcl33$465
SotalolSotalol Hcl24$454
Losartan Potassium60$445
Rosuvastatin Calcium28$434
Midodrine Hcl11$353
Valsartan14$325
Spironolactone20$293
Furosemide53$237
Amlodipine Besylate61$222
Hydrochlorothiazide26$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$62,32956 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 130 cardiovascular disease providers in Arkansas.

Other cardiovascular disease in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →